Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Gland Pharma Limited (GLAND.NS)
Hyderabad, IN
Gland Pharma Limited, established in Hyderabad, India, in 1978, is a pharmaceutical company that specializes in the creation, production, and global distribution of generic injectable medications. Its product line features key active pharmaceutical ingredients such as heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, among others. The company's extensive therapeutic portfolio encompasses anti-infectives, anesthetics, anticoagulants, antimalarials, cardiovascular drugs, gastrointestinal treatments, pain management, hormones, fertility aids, anti-cancer agents, gynecological remedies, neurological and central nervous system medications, respiratory treatments, blood-related products, ophthalmological and otological solutions, orthopedics, hematinics, and various vitamins, minerals, and nutrients. Additionally, Gland Pharma provides contract development services. The company primarily operates on a business-to-business (B2B) model, distributing its products across major markets including the United States, Europe, Canada, Australia, India, and other international territories. Gland Pharma Limited functions as a subsidiary of Fosun Pharma Industrial Pte. Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +15.43% | +15.33% | +19.98% | +16.60% | +20.47% | +25.24% | +45.33% | +61.91% | -29.58% | +18.52% | +18.52% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | +1 |
| Buy | 5 | 0 |
| Hold | 1 | 0 |
| Sell | 3 | 0 |
| Strong Sell | 2 | 0 |
-
Revenue growth Drug Manufacturers - General: +6.6%+14.5% ★ Q1'26: +22.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+46.9% ★ Q1'26: +96.4% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+7.5% Q1'26: +22.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+18.8% Q1'26: +23.2% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+11.6% ★ Q1'26: +16.1% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%+0.1% Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×0.17× ★ Q1'26: 0.14× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 10 Rev. Ana. 9 EPS Ana. |
Mar 2027 9 Rev. Ana. 9 EPS Ana. |
Mar 2028 10 Rev. Ana. 11 EPS Ana. |
Mar 2029 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
34.63B
est: 34.11B (+1.5%)
|
44.01B
est: 44.05B (-0.1%)
|
36.25B
est: 36.25B (+0.0%)
|
56.65B
est: 58.58B (-3.3%)
|
56.17B
est: 57.60B (-2.5%)
|
63.60B
62.32B – 64.34B
+10.4% YoY
|
73.18B
71.10B – 74.76B
+15.1% YoY
|
83.17B
76.69B – 86.12B
+13.6% YoY
|
95.33B
94.57B – 96.09B
+14.6% YoY
|
| EBITDA |
13.02B
est: 9.90B (+31.5%)
|
15.10B
est: 12.79B (+18.1%)
|
10.31B
est: 10.52B (-2.0%)
|
12.97B
est: 15.57B (-16.7%)
|
12.31B
est: 15.31B (-19.6%)
|
16.91B
16.57B – 17.10B
+10.4% YoY
|
19.45B
18.90B – 19.87B
+15.1% YoY
|
22.11B
20.39B – 22.89B
+13.6% YoY
|
25.34B
25.14B – 25.54B
+14.6% YoY
|
| EBIT |
12.03B
est: 8.43B (+42.7%)
|
14.00B
est: 10.89B (+28.5%)
|
8.84B
est: 8.96B (-1.3%)
|
9.71B
est: 12.61B (-23.0%)
|
8.72B
est: 12.40B (-29.7%)
|
13.69B
13.42B – 13.85B
+10.4% YoY
|
15.76B
15.31B – 16.10B
+15.1% YoY
|
17.91B
16.51B – 18.54B
+13.6% YoY
|
20.52B
20.36B – 20.69B
+14.6% YoY
|
| Net Income |
9.97B
est: 9.95B (+0.2%)
|
12.12B
est: 12.69B (-4.5%)
|
7.81B
est: 8.44B (-7.5%)
|
7.72B
est: 7.22B (+7.0%)
|
6.99B
est: 7.03B (-0.6%)
|
10.27B
9.15B – 10.47B
+46.1% YoY
|
12.61B
11.32B – 13.22B
+22.8% YoY
|
15.41B
11.33B – 17.14B
+22.1% YoY
|
17.96B
17.36B – 19.40B
+16.6% YoY
|
| SGA |
3.12B
est: 5.18B (-39.7%)
|
3.40B
est: 6.69B (-49.2%)
|
4.07B
est: 5.50B (-26.1%)
|
12.88B
est: 8.76B (+47.1%)
|
14.17B
est: 8.61B (+64.5%)
|
9.51B
9.32B – 9.62B
+10.4% YoY
|
10.94B
10.63B – 11.18B
+15.1% YoY
|
12.43B
11.46B – 12.87B
+13.6% YoY
|
14.25B
14.14B – 14.36B
+14.6% YoY
|
| EPS |
63.07
est: 60.41 (+4.4%)
|
73.81
est: 77.05 (-4.2%)
|
47.44
est: 51.28 (-7.5%)
|
46.90
est: 43.84 (+7.0%)
|
42.40
est: 43.35 (-2.2%)
|
58.42
55.50 – 63.46
+34.8% YoY
|
73.58
68.63 – 80.17
+25.9% YoY
|
89.84
68.66 – 103.92
+22.1% YoY
|
113.33
105.27 – 117.59
+26.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-15 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Emerging Markets SmallCap Dividend Fund DGS | 0.06% | 1.02M | 0.58% |
| 2 | WisdomTree India Earnings Fund EPI | 0.05% | 1.07M | 0.84% |
| 3 | WisdomTree Emerging Markets ex-State-Owned Enterprises Fund XSOE | 0.05% | 1.09M | 0.32% |
| 4 | WisdomTree True Emerging Markets Fund XC | 0.04% | 33.4K | 0.32% |
| 5 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.01% | 1.13M | 0.39% |
| 6 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.01% | 30.3K | 0.56% |
| 7 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.01% | 53.8K | 0.44% |
| 8 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.01% | 810.6K | 0.29% |
| 9 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.00% | 622.2K | 0.07% |
| 10 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 341.6K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Srinivas Sadu | Executive Chairman | 86M | male |
| Shyamakant Giri | Chief Executive Officer | 26M | male |
| Ravi Shekhar Mitra | Chief Financial Officer | 26M | male |
| Sampath Kumar Pallerlamudi | Company Secretary & Vice-President of Compliance & CSR | 8M | male |
| Satnam Singh Loomba | Chief Operating Officer | — | male |
| Shriniwas Dange | Head of Investor Relations | — | male |
| Surinder Koul | Head of Domestic Marketing | — | male |
| Prabhakara Sastry | Head of R&D | — | male |
| Wriddhee Maitra | Vice President of Human Resources | — | male |
| Prasadha Rao Lysetti | Senior VP & Head of Operations | — | male |
| Raghuramachandra Rao | Head of Quality | — | male |
| Rong Wu | Financial Controller | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GLAND.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
